(Source: CASI Pharmaceuticals Inc) ROCKVILLE, Md., Nov. 4, 2015 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces the dosing of the first patient in a Phase 2 clinical trial in patients with advanced fibrolamellar carcinoma (FLC) at Memorial Sloan-Kettering Cancer Center. The trial entitled 'A Phase 2 Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma (FLC)' will be evaluating the safety and efficacy of ENMD-2076, an orally-active Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and...
↧